International Institute for Population Sciences

‘Getting the Village Back Together’: ChristianaCare’s Plan for Reducing Breast Cancer Disparities in Delaware

Retrieved on: 
Wednesday, November 1, 2023
Woman, Glomus tumor, Ashkenazi Jews, Incidence, Population Health Management, Housing, Health equity, Bank, Biomarker, Obesity, Racism, Gynecologic cancer disparities in the United States, Mortality, Colorectal cancer, Diabetes, International Institute for Population Sciences, Community, ChristianaCare, TNBC, Trust, Cancer, Disease, Risk, Siegel, National Cancer Institute, Breast cancer, Triple-negative breast cancer, Gibbs Cancer Center & Research Institute, Death, Bangladesh Technical Education Board, Dietary supplement, Birth control, Medical imaging, Black

Wilmington, Delaware, Nov. 01, 2023 (GLOBE NEWSWIRE) -- There’s a tried and proven pathway to reducing racial disparities in cancer in Delaware.

Key Points: 
  • Wilmington, Delaware, Nov. 01, 2023 (GLOBE NEWSWIRE) -- There’s a tried and proven pathway to reducing racial disparities in cancer in Delaware.
  • The commentary — "Reducing Racial Disparities in Breast Cancer: Getting the Village Back Together" — is a call to action for community members, health care providers and other stakeholders to partner together to address disparities in breast cancer.
  • According to the National Cancer Institute, Delaware leads the country in incidences of late-stage breast cancer among women younger than 50.
  • “We are excited at the possibility of bringing the larger village back together again to tackle the disparities in breast cancer.

ICF Reports Second Quarter 2023 Results

Retrieved on: 
Thursday, August 3, 2023
Maintenance, Book, Justice, U.S. Department of the Interior, Office of Inspector General, CMY, ICF, Education, Contract awarding, Office of Inspector General, U.S. Department of Health and Human Services, Firefighter, Public, Human services, Victim, Aviation, Tax, Development aid, GAAP, Research, ICFI, Carbon, Corporate social responsibility, Marketing, Sale, Government, Organization, TTA, Local government, EBITDA, Acquisition, Division, Engineering, OVC, Interior, Growth, EPS, Climate, Federation, Health, Adjustment, Commercial, Environment, International Institute for Population Sciences, Pharmaceutical industry, Clothing, Cryptocurrency, Video game, Renewable energy, Film industry, Fine chemical, Airline, Crime

RESTON, Va., Aug. 3, 2023 /PRNewswire/ -- ICF (NASDAQ:ICFI), a global consulting and technology services provider, reported results for the second quarter ended June 30, 2023. 

Key Points: 
  • Our business development pipeline reached a record $10.3 billion at the end of the second quarter, indicative of the significant growth opportunities ahead.
  • Second quarter 2023 revenue increased 18.2% to $500.1 million from $423.1 million in the second quarter of 2022.
  • Second quarter 2023 net income and diluted EPS includes a one-time tax benefit and other tax optimization strategies of $0.21 per share.
  • Total backlog was $3.6 billion at the end of the second quarter of 2023.

Heligenics Unveils A First-Of-Its-Kind Precision Prescription Test For Breast Cancer Therapeutics

Retrieved on: 
Tuesday, June 13, 2023
Drug development, Therapy, Genetics, Genomics, Research, Multimedia, Pharmacotherapy, Patient, Neoplasm, International Institute for Population Sciences, Translational Genomics Research Institute, FDA, Library, Breast cancer, Pharmaceutical industry, Medical imaging, Vaccine, Medical device

LAS VEGAS, June 13, 2023 /PRNewswire/ -- Heligenics, a cutting-edge biotech company, announces a first-of-its-kind precision genetic test to select among drugs to treat breast cancer.

Key Points: 
  • LAS VEGAS, June 13, 2023 /PRNewswire/ -- Heligenics, a cutting-edge biotech company, announces a first-of-its-kind precision genetic test to select among drugs to treat breast cancer.
  • Heligenics revolutionized selection of the right drug with its first-of-its-kind genetic test for breast cancer that chooses among 3 FDA-approved drugs.
  • Heligenics has started with 3 breast cancer drugs called Tykerb™, Tukysa™, and Nerlynx™.
  • They provide comprehensive genomic solutions to pharmaceutical and biotech companies, as well as healthcare providers, advancing personalized medicine and precision therapeutics.

Lundquist Institute Investigators Co-Author Paper in JAMA on Coronary Heart Disease (CHD) Risk Prediction

Retrieved on: 
Thursday, June 1, 2023
CT scan, Heart, CT, TLI, Genomics, Moyamoya disease, Calcium, American Medical Association, Genetics, Journal, Patient, Risk, Dark Ages, Division, Translational Genomics Research Institute, Death, Harbor–UCLA Medical Center, CHD, Northwestern University, International Institute for Population Sciences, Medical imaging, MD, Cardiology

Los Angeles, June 01, 2023 (GLOBE NEWSWIRE) -- The Lundquist Institute (TLI) announced today that Jerome Rotter, MD, and Matthew Budoff, MD, two of TLI’s investigators, are co-authors of a paper, “Coronary Artery Calcium Score and Polygenic Risk Score for the Prediction of Coronary Heath Disease Events,” in JAMA (the Journal of the American Medical Association).

Key Points: 
  • Los Angeles, June 01, 2023 (GLOBE NEWSWIRE) -- The Lundquist Institute (TLI) announced today that Jerome Rotter, MD, and Matthew Budoff, MD, two of TLI’s investigators, are co-authors of a paper, “Coronary Artery Calcium Score and Polygenic Risk Score for the Prediction of Coronary Heath Disease Events,” in JAMA (the Journal of the American Medical Association).
  • The study assessed whether a coronary artery calcium score was associated with better discrimination than the polygenic risk score for the risk prediction of coronary heart disease (CHD) in middle-aged to older adults from the United States and Netherlands.
  • Both tools — polygenic risk and coronary artery calcium — are being used in coronary health disease risk assessment but they have never been directly compared head-to-head.
  • “What we found is an excellent way to identify who is at risk for coronary heart disease in middle-age,” said Dr. Rotter, Lundquist Investigator and Director of the TLI Institute for Translational Genomics and Population Sciences.

Dr. Abdel Nuriddin Inducted into Marquis' Who's Who

Retrieved on: 
Wednesday, May 17, 2023
Executive producer, Genesis Health System, Rick Roberts (executive producer), Who, Muhammad Speaks, International Institute for Population Sciences, Doctor of Philosophy, Growth hacking, Patient, MA, United Kingdom, Health, Alternative medicine, Nursing, Naturopathy

"I am truly humbled to be recognized by this distinguished company," Nuriddin continued.

Key Points: 
  • "I am truly humbled to be recognized by this distinguished company," Nuriddin continued.
  • As a result, Dr. Nuriddin is a Class of 2008 Diplomat of Holistic Iridology via The International Institute of Iridology.
  • Currently, Dr. Nuriddin is the owner and operator of Genesis Health & Nutrition Center, LLC in Greensboro, North Carolina.
  • To be recognized by a publication like Who's Who for doing so is simply icing on the cake," Nuriddin concluded.

World Lung Cancer Day: City of Hope Approved for $7 Million to Study Interventions for Lung Cancer in Older Adults

Retrieved on: 
Monday, August 1, 2022
Research, Surgery, Seniors, Clinical Trials, Stem Cells, General Health, Consumer, Health, Science, Oncology, Patient, Division, Diabetes, Northern Virginia Sun, Walking, Center, Physical activity, Mental, Research, Twitter, Instagram, PCORI, CAR, Telephone, Cardiothoracic surgery, Lung cancer, Friends, Continuum, International Institute for Population Sciences, Translational Genomics Research Institute, Haematopoietic system, Patient-Centered Outcomes Research Institute, City, National Cancer Institute, City of Hope, Family, Geriatrics, News, Organization, Quality of life, YouTube, Immunotherapy, Technology, Caregiver, Cancer Treatment Centers of America, LinkedIn, Department, Biology, U.S. News & World Report, Population, Pharmaceutical industry, Hospital, Health insurance, Medicine, Dietary supplement, Facebook, Ageing, Hope, Cancer

This study tests a personalized walking and lower extremity strengthening program that is delivered by telephone before and after surgery.

Key Points: 
  • This study tests a personalized walking and lower extremity strengthening program that is delivered by telephone before and after surgery.
  • We think this will help older adults recover more quickly and become more active even after the study is over.
  • There is a critical need to develop interventions specifically for older adults that improve quality of life and reduce complications from lung cancer surgery.
  • The study, Perioperative Physical Activity in Older Adults Undergoing Lung Cancer Surgery, is part of PCORIs Healthy Aging: Optimizing Physical and Mental Functioning Across the Continuum initiative.

Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases

Retrieved on: 
Thursday, February 3, 2022
Oncology, Health, Genetics, Research, Science, Biotechnology, Diagnosis, Data, Risk, Patient, Registry, SEER, List of life sciences, International Institute for Population Sciences, Sentinel lymph node, Uveal melanoma, National, National Cancer Institute, SEC, Program, Poster, SRP, Twitter, CM, Securities Act of 1933, Research, COVID-19, Skin cancer, Population, Cancer, Instagram, Surveillance, Recurrence, Epidemiology, Pooled analysis, Skin, Gene, Company, NCI, Personal Data Privacy and Security Act of 2009, Time, Survival, Securities Exchange Act of 1934, Disease management, DecisionDx-UM, Data collection, Data analysis, SLN, LinkedIn, Conference, Nasdaq, Atopic dermatitis, Vaccine, Mobile phone, Medical device, Medical imaging, Pharmaceutical industry, Facebook, DecisionDx-Melanoma, the SEER Program, Castle Biosciences, DECISIONDX-MELANOMA, THE SEER PROGRAM, CASTLE BIOSCIENCES

The Company expects to continue collaborating with the NCI to link the SEER registries CM cases diagnosed post-2018 with DecisionDx-Melanoma test results.

Key Points: 
  • The Company expects to continue collaborating with the NCI to link the SEER registries CM cases diagnosed post-2018 with DecisionDx-Melanoma test results.
  • We are excited to collaborate with the NCI to link DecisionDx-Melanoma test results with the SEER registries data, said Derek Maetzold, president and chief executive officer of Castle Biosciences.
  • The SEER registries linked CM cases in the registry to DecisionDx-Melanoma testing data provided by Castle Biosciences.
  • The SEER Program registries collect data on cancer cases diagnosed in their catchment area from various locations and sources throughout the United States.

Future of Cancer Prevention, Policy Outlined in a Special Behavioral Medicine Journal

Retrieved on: 
Tuesday, November 30, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Feinstein Institute for Medical Research, Patient, National, Government, Fortis Healthcare, Population health, CEO, Mental health, Credit, Technology, Death, Diagnosis, MD, Northwell Health, Cancer, Behavior, Fox Chase Cancer Center, Doctor of Philosophy, National Cancer Institute, Institute, TBM, Society, Genetics, Collection, Molecular medicine, Science, Medical research, NCI, Journal, International Institute for Population Sciences, Control, Medicine, Division, LinkedIn, Multimedia, Autoimmunity, Strathcona County, Pharmaceutical industry

As 2021 marks the 50th anniversary of President Richard Nixon declaring war on cancer, researchers from The Feinstein Institutes for Medical Research , in collaboration with the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI) and Fox Chase Cancer Center published today a special edition of the Society of Behavioral Medicines journal Translational Behavioral Medicine: Practice, Policy, Research (TBM) .

Key Points: 
  • As 2021 marks the 50th anniversary of President Richard Nixon declaring war on cancer, researchers from The Feinstein Institutes for Medical Research , in collaboration with the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI) and Fox Chase Cancer Center published today a special edition of the Society of Behavioral Medicines journal Translational Behavioral Medicine: Practice, Policy, Research (TBM) .
  • View the full release here: https://www.businesswire.com/news/home/20211130005975/en/
    Michael Diefenbach, PhD, professor in the Institute of Health System Science at the Feinstein Institutes was one of the editors on the special edition of the journal.
  • From detection to diagnosis and survivorship, this collection of articles are meant to provide a roadmap for future investigators to expand on behavioral cancer research.
  • The overall goal of the journal is to create an impact on cancer prevention and control research, practice and policy over the next decade.

LUNGevity Foundation Awards Inaugural Health Equity for Communities Research Awards

Retrieved on: 
Tuesday, November 30, 2021
Research, Health equity, Patient, Policy, Senior, Caregiver, Cancer, Prostate, Conference, Lung cancer, Smoking, Communications Research Centre Canada, General manager, Population, CBPR, Partnership, HCPS, Public, Human, Bristol Myers Squibb, Community-based participatory research, Breast, Doctor of Philosophy, Education, Milken Institute School of Public Health, Program, Smoker, Latinx, BUT, Survival, Incidence, Helpline, Community health, Public policy, Tobacco, International Institute for Population Sciences, Diversity, Survivor, Multimedia, Department, Strathcona County, Quality of life, Birth control, Medical imaging, Medical device, Pharmaceutical industry

LUNGevity's Health Equity for Communities Research Award supports young researchers interested in lung cancer CBPR as a way to establish quality outcomes and health equity in high-risk populations.

Key Points: 
  • LUNGevity's Health Equity for Communities Research Award supports young researchers interested in lung cancer CBPR as a way to establish quality outcomes and health equity in high-risk populations.
  • This year, LUNGevity is supporting twoHealth Equity for Communities Research Awards.Each award is for a maximum of $250,000 for 2 years.
  • Experts from LUNGevity's Health Equity Council, chaired by Chief Health Equity and Diversity Officer Jeanne Regnante, guided the selection of the awardees.
  • "We are pleased to support the 2021 inaugural Health Equity in Communities research awards.

Lung Cancer Research Foundation Announces 2021 Scientific Research Grant Awards

Retrieved on: 
Thursday, November 18, 2021
ICIS, Diagnosis, Recurrence, MD, Bristol Myers Squibb, Assistant professor, Doctor of Philosophy, Social determinants of health, Hope, School, Neoplasm, Board of directors, Board, Yale University, Associate, Lung cancer, United States Air Force Scientific Advisory Board, Division, Department, Thomas, Minority, Cardiothoracic surgery, Prostate Cancer Foundation, Research, International Institute for Population Sciences, TEAD, Medical school, National Order of Scientific Merit, Partnership, AstraZeneca, Survival, Lymph, Survivor, Quality of life, Patient, Foundation, Novartis, EGFR, Program, City, Gaps, Health equity, Science, Motivation, Chairperson, Pharmaceutical industry, Uranium

"I am honored to receive the William C. Rippe Award for Distinguished Research in Lung Cancer from the Lung Cancer Research Foundation.

Key Points: 
  • "I am honored to receive the William C. Rippe Award for Distinguished Research in Lung Cancer from the Lung Cancer Research Foundation.
  • The 2021 Pilot Grant Program award recipients include:
    The 2021 Disparities in Lung Cancer Research Grant Program award recipients include:
    The 2021 LCRF-AstraZeneca Resistance Grant award recipients include:
    Targeting YAP/TEAD bypass activation in Osimertinib-induced drug tolerant cells: a strategy to overcoming tumor recurrence and therapeutic resistance in EGFR-mutant non-small cell lung cancers
    For more information about LCRF and the Scientific Grant Program, visit LCRF.org/Research.
  • The Lung Cancer Research Foundation (LCRF) is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer.
  • LCRF's mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer.